BDX: EVP Garrison Retires; BioPharma to CEO Polen

Published: July 22, 2026

BECTON DICKINSON & CO

Direct News

Becton Dickinson & Co. (BDX) EVP Garrison is retiring (announcement on July 22, 2026).
BD's BioPharma segment will report directly to CEO Polen effective with the organizational change.
Q1 FY2026 (ended Dec. 31, 2025) snapshot: net income $382 million, diluted EPS $1.34, dividends per share $1.05.
Company completed spin-off of Biosciences & Diagnostic Solutions to Waters Corporation and received a $4.0 billion cash distribution.

Historical Context

This personnel and reporting update comes after several material corporate actions disclosed through FY2025 and Q1 FY2026 filings. Notable prior events recorded in company filings include: - Completion of the spin-off of the Biosciences and Diagnostic Solutions business to Waters Corporation; BD received a $4.0 billion cash distribution and reclassified the spun-off business's historical results as discontinued operations. - Q1 FY2026 (ended Dec. 31, 2025) financial snapshot: net income $382 million, diluted EPS $1.34, dividends per share $1.05, and 284,741,809 shares outstanding. - Capital-return activity: $250 million of repurchases in Q1 FY2026 and a planned $2.0 billion ASR in Q2 FY2026, plus an authorization for 10 million additional share repurchases. - Governance actions and filings through 2025 that remain part of the record: bylaw amendments (April 29, 2025), a Notice of Pendency and Proposed Settlement furnished June 16, 2025, and board composition updates (March 26, 2025). As of July 22, 2026, the announcement should be viewed against these recent strategic and capital-allocation moves; however, filings available in the provided excerpts do not supply detailed segment revenue splits, patent or moat metrics, or definitive operational projections tied to the executive change.

What changed

Becton Dickinson announced that EVP Garrison will retire and that the BioPharma segment will report to CEO Polen. The release does not provide an effective date for the retirement or further detail on any interim leadership assignments beyond the reporting line to the CEO. The core change is a direct reporting realignment that centralizes BioPharma under the CEO's purview.

Financial and capital-allocation context

The personnel and reporting change arrives after Q1 FY2026 results (period ended December 31, 2025) in which the company reported net income of $382 million and diluted EPS of $1.34. Q1 disclosures list dividends per share of $1.05, 284,741,809 shares outstanding, total assets of $54,841 million, shareholders' equity of $25,282 million, and cash and equivalents of $851 million (closing balance $1,025 million including restricted cash). Separately, BD completed the spin-off of its Biosciences and Diagnostic Solutions business to Waters Corporation and received a $4.0 billion cash distribution funded by the spin-off entity's debt. Management used or signaled use of proceeds for capital returns: $250 million in share repurchases in Q1 FY2026 and a planned $2.0 billion accelerated share repurchase (ASR) in Q2 FY2026, alongside an open authorization for an additional 10 million shares.

Investor implications and monitoring points

For investors, the immediate implications are organizational and governance-focused rather than financial: consolidating the BioPharma reporting line to the CEO may speed decision-making or oversight for that business, but filings provided do not quantify expected cost savings or revenue impact from the change. Key items for investors to monitor in subsequent disclosures include: - Any interim or permanent leadership appointments and timing tied to EVP Garrison’s retirement. - Segment reporting detail for BioPharma (revenues, margins) under CEO oversight; Q1 filings lacked a granular segment revenue breakdown. - Capital-allocation updates following the $4.0 billion spin-off distribution and progress on the $2.0 billion ASR and broader repurchase program. - Legal and regulatory developments cited in filings (a Notice of Pendency and Proposed Settlement furnished June 16, 2025) and governance changes (bylaw amendments) that could affect shareholder outcomes. The company’s disclosed risks—accumulated foreign currency translation losses of $1,336 million, ongoing assessment of upcoming FASB disclosure changes, and reclassification of spun-off results as discontinued operations—remain relevant when evaluating the impact of executive transitions on near-term performance.

Investor FAQ

The most effective approach is to maintain a factual perspective. Keep a close watch on further developments at BECTON DICKINSON & CO as they unfold. Use primary source data to validate your investment thesis rather than relying on delayed secondary reports.

You can set up an automated tracker on Portrak. Our system monitors official SEC filings in real-time, delivering the most critical insights to your phone or inbox seconds after publication—frequently before the information reaches major financial news platforms.

We believe quality intelligence should be accessible. Our business model is supported by professional investors with large, complex portfolios who utilize Portrak Pro. These users pay to automate the monitoring of extensive watchlists, saving hundreds of hours in research time, which allows us to keep the standard service free for individual investors tracking their core positions.

Setting up your automated intelligence pipeline is a simple 3-step process:

Create Your Free Account

Select Your Focus

Use the search bar to find companies like BECTON DICKINSON & CO. Choose between monitoring specific events or receiving general market-moving intelligence. Our AI automatically determines what’s critical based on real-time market data and the company’s current profile.

Receive Real-Time Intelligence

Once activated, all official filings are analyzed instantly. Insights are delivered directly to your email or as a push notification if you use the Portrak mobile app.

Also available as a mobile app for iOS & Android—search for "Portrak"

More Strategic Insights

BAX

Aug 4, 2026

Direct News

Historical Context

What changed

Financial and capital-allocation context

Investor implications and monitoring points

Investor FAQ

More Strategic Insights

BAX: Interim CFO Anita Zielinski Resigns

Ameren Raises Equity Program to $2.27B (AEE)

CYCUW: Cycurion Acquires Kustom Video Division

Michael J. Petro Named CFO at Martin Marietta